Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial. This brings the total number of adults with Parkinson’s who received sasineprocel in the…
News
Gut bacteria that produce vitamin B6 may help nerve cells in the brain produce dopamine, a chemical involved in motor control that is missing in Parkinson’s disease, according to an animal study. The research in worms and mice adds to a growing understanding of how the gut-brain axis is…
The first meeting of the National Parkinson’s Project Advisory Council, held on June 29, ended with a commitment to deliver a first report by summer 2027, while acknowledging that more clarity is needed on the federal funding required for Parkinson’s disease research and care. The National Parkinson’s Project…
Many people with advanced Parkinson’s disease may actually not have widespread accumulation of toxic protein clumps known as Lewy bodies, which have long been thought to accompany the neurological condition in its later stages, according to a new study from U.S. researchers. The scientists found that most…
A growing body of research suggests that the gut microbiome — the community of bacteria and other microscopic organisms that live in the human digestive tract — may play key roles in the development and progression of Parkinson’s disease. Data suggest that it may be possible to develop Parkinson’s…
The U.S. Food and Drug Administration (FDA) has given Gain Therapeutics a green light to launch a clinical trial — to run across three continents — testing GT-02287, an oral therapy designed to prevent the formation of toxic protein clumps in Parkinson’s disease. The agency clearance follows positive early…
Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these participants received a new, commercial-ready formulation of the cell therapy designed to make future manufacturing and treatment…
A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and carbidopa sold in the U.S. under the brand name Crexont — for people with Parkinson’s disease in the European Union who experience motor fluctuations despite treatment. The EMA’s…
Parkinson’s advocacy organizations are urging the newly established National Parkinson’s Project Advisory Council to move quickly to implement the project, a U.S. strategy to prevent, diagnose, treat, and ultimately cure Parkinson’s disease. The American Parkinson Disease Association (APDA), The Michael J. Fox Foundation for Parkinson’s Research (MJFF),…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted $2.74 million to X-tosis to support the preclinical development of XTS001, the company’s lead candidate for the treatment of Parkinson’s disease. The funding, granted through MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, will support laboratory research…
Recent Posts
- Engaging with others by asking questions can make them feel seen
- Tai Chi may ease Parkinson’s motor symptoms, improve physical function
- FDA fast-tracks experimental vaccine aiming to slow early Parkinson’s
- Not every day was a good Parkinson’s day or a bad Parkinson’s day
- Guest Voice: How Parkinson’s gave me a new purpose in life